EP0713391A1 - Procede d'inhibition de la production de virus de l'immunodeficience chez l'homme au moyen d'azaspiranes substitues - Google Patents

Procede d'inhibition de la production de virus de l'immunodeficience chez l'homme au moyen d'azaspiranes substitues

Info

Publication number
EP0713391A1
EP0713391A1 EP94922684A EP94922684A EP0713391A1 EP 0713391 A1 EP0713391 A1 EP 0713391A1 EP 94922684 A EP94922684 A EP 94922684A EP 94922684 A EP94922684 A EP 94922684A EP 0713391 A1 EP0713391 A1 EP 0713391A1
Authority
EP
European Patent Office
Prior art keywords
compound
hiv
inhibiting
formula
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94922684A
Other languages
German (de)
English (en)
Other versions
EP0713391A4 (fr
Inventor
Alison Mary Badger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0713391A1 publication Critical patent/EP0713391A1/fr
Publication of EP0713391A4 publication Critical patent/EP0713391A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Definitions

  • This invention relates to a method of inhibiting the production of infectious human immunodeficiency viruses (HIV) in HIV seropositive humans which comprises administering to such human an effective amount of a substituted azaspirane.
  • HIV infectious human immunodeficiency viruses
  • CD8+ T cells have been shown to inhibit the replication of HIV in cultures of CD4+ cells from asymptomatic HTV seropositive individuals (Brinchmann et al. CD8+ T cells J Immunol. 1442961-2966 (1990)).
  • the immunosuppressive compound cyclosporin A (CsA) has demonstrated a protective effect in several animal models of viral infection. Particularly, chronic treatment with CsA before and after infection with LP-BM5 murine leukemia virus has proven effective against the development of immunodeficiency disease (Cemy, A. et al. Eur. J. Immunol. 21: 1747-50 (1991)).
  • Badger, et al., U.S. Patent No.4,963,557 discloses compounds of the formula (I) wherein: n is 3-7; m is 1 or 2; R and R ⁇ are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R* and R ⁇ when taken together is 5-10; or R* and R2 together form a cyclic alkyl group having 3-7 carbon atoms; R ⁇ and R ⁇ are the same or different and are selected from hydrogen or straight chain alkyl having 1- 3 carbon atoms; or R ⁇ and R ⁇ are joined together with the nitrogen atom to form a heterocyclic group having 5-8 atoms; or a pharmaceutically acceptable salt or hydrate or solvate thereof.
  • Badger I discloses compounds of Formula I as a class of novel compounds which induce an immunomodulatory effect which is characterized by the stimulation of suppressor cell activity.
  • Rl and R ⁇ are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by Rl and R ⁇ when taken together is 5-10; or R 1 and R ⁇ together form a cyclic alkyl group having 3-7 carbon atoms;
  • R3 and R ⁇ are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R3 and R ⁇ are joined together with the nitrogen atom to form a heterocyclic group having 5-8 atoms; or a pharmaceutically acceptable salt or hydrate or solvate thereof.
  • a preferred compound used in the novel method is the dihydrochloride salt of a compound of Formula (I) where R* and R ⁇ are propyl, R ⁇ and R 4 are methyl, m is 1 and n is 3 which is N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2- propanamine dihydrochloride.
  • a particularly preferred compound used in the novel method is the dihydrochloride salt of a compound of Formula (I) where Rl and R ⁇ are propyl, R3 and R 4 are ethyl, m is 1 and n is 3 which is N,N-diethyl-8,8-dipropyl-2- azaspiro[4.5]decane-2-propanamine dihydrochloride.
  • a particularly preferred compound used in the novel method is the dihydrochloride salt of a compound of Formula (I) where R* and R ⁇ are propyl, R3 and R 4 are joined together with the nitrogen to form a piperidine ring, m is 1 and n is 3 which is 8,8-dipropyl-2-azaspiro[4.5]decane-2-piperidinopropyl dihydrochloride.
  • This invention discloses compounds of Formula (I) and pharmaceutically acceptable salts or hydrates or solvates thereof as being useful for inhibiting the production of infectious HTV in HIV seropositive humans.
  • the compounds of Formula I are tested for their ability to inhibit the production of infectious HIV in the assay described in Sperber, et al., AIDS Research and Human Retroviruses. 9 No.l. 91-98.
  • This invention relates to a method of inhibiting the production of infectious HIV which comprises administering to an HIV seropositive human an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof.
  • a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof can be administered to such human in a conventional dosage form prepared by combining a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof, with a conventional pharmaceutically acceptable carrier or diluent according to known techniques, such as those described in Badger (I), U.S. Patent No. 4,963,557.
  • a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof is administered to an HIV seropositive human in an amount sufficient to inhibit the production of infectious HIV
  • the route of administration of the Formula (I) ("active ingredient”) compound is not critical but is usually oral or parenteral, preferably oral.
  • parenteral as used herein includes intravenous, intramuscular, subcutaneous, intranasal, intrarectal, transdermal, intravaginal or intraperitoneal administration.
  • the subcutaneous and intramuscular forms of parenteral administration are generally preferred.
  • the daily parenteral dosage regimen will preferably be from about 0.01 mg/kg to about 10 mg/kg of total body weight, most preferably from about 0.1 mg kg to about 1 mg/kg.
  • each parenteral dosage unit will contain the active ingredient in an amount of from about 0.1 mg to about 100 mg.
  • the compounds of Formula (I) which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agent.
  • a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agent.
  • a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such earners include magnesium stearate, starch, lactose, sucrose and cellulose.
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures.
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • the daily oral dosage regimen will preferably be from about 0.01 mg/kg to about 10 mg/kg of total body weight.
  • each oral dosage unit will contain the active ingredient in an amount of from about 0.1 mg to about 100 mg.
  • an active ingredient While it is possible for an active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation.
  • the optimal quantity and spacing of individual dosages of a compound of formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof given per day and duration of therapy, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
  • the method of this invention of inhibiting the production of infectious HIV in HIV seropositive humans comprises administering to a subject in need of such inhibition an effective infectious HIV inhibiting amount of a pharmaceutically active compound of the present invention.
  • the invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in the inhibition of infectious HIV in HIV seropositive humans.
  • the invention also provides for a pharmaceutical composition for use in the inhibition of the production of infectious HIV in HIV seropositive humans which comprises a compound of Formula I and a pharmaceutically acceptable carrier.
  • the invention also provides for a process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and a compound of Formula I which comprises bringing the compound of Formula I into association with the pharmaceutically acceptable carrier or diluent.
  • the compounds of the present invention can be co-administered with further active ingredients, such as compounds known to prevent or delay the occurrence of AIDS in HIV seropositive humans such as retrovir (the brand name for zidovudine, formerly called azidothymidine (AZT)).
  • further active ingredients such as compounds known to prevent or delay the occurrence of AIDS in HIV seropositive humans such as retrovir (the brand name for zidovudine, formerly called azidothymidine (AZT)).
  • An injectable form for administering Formula (I) compounds is produced by stirring 1.5% by weight of N,N-diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2- propanamine dihydrochloride in 10% by volume propylene glycol in water.
  • Example 3 Tablet Composition
  • sucrose, calcium sulfate dihydrate and Formula (I) compound shown in Table ⁇ below are mixed and granulated in the proportions shown with a 10% gelatin solution.
  • the wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne un procédé d'inhibition de la production de virus infectueux de l'immunodéficience chez l'homme (VIH) chez des individus séropositifs consistant en l'administration auxdits individus d'une quantité efficace d'azaspirane substitué.
EP94922684A 1993-07-23 1994-07-22 Procede d'inhibition de la production de virus de l'immunodeficience chez l'homme au moyen d'azaspiranes substitues Withdrawn EP0713391A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939315306A GB9315306D0 (en) 1993-07-23 1993-07-23 Methods
GB9315306 1993-07-23
PCT/US1994/008275 WO1995003041A1 (fr) 1993-07-23 1994-07-22 Procede d'inhibition de la production de virus de l'immunodeficience chez l'homme au moyen d'azaspiranes substitues

Publications (2)

Publication Number Publication Date
EP0713391A1 true EP0713391A1 (fr) 1996-05-29
EP0713391A4 EP0713391A4 (fr) 1998-09-09

Family

ID=10739328

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94922684A Withdrawn EP0713391A4 (fr) 1993-07-23 1994-07-22 Procede d'inhibition de la production de virus de l'immunodeficience chez l'homme au moyen d'azaspiranes substitues

Country Status (8)

Country Link
EP (1) EP0713391A4 (fr)
CN (1) CN1130870A (fr)
AU (1) AU7370894A (fr)
CA (1) CA2167841A1 (fr)
GB (1) GB9315306D0 (fr)
NZ (1) NZ269990A (fr)
WO (1) WO1995003041A1 (fr)
ZA (1) ZA945416B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9315340D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
GB9315351D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
BR9601909A (pt) * 1995-07-13 1999-10-13 Smithkline Beecham Corp N,n-dietil-8,8-dipropil-2-azaspiro(4,5)decano-2-propan amina dimaleato
SK156698A3 (en) * 1996-05-17 1999-06-11 Anormed Inc Use of substituted azaspirane in the treatment of asthma
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014462A1 (fr) * 1991-02-19 1992-09-03 Smithkline Beecham Corporation Inhibiteurs de cytokines
WO1993014760A2 (fr) * 1992-01-28 1993-08-05 Smithkline Beecham Corporation Procedes
WO1993015735A1 (fr) * 1992-01-28 1993-08-19 Smithkline Beecham Corporation Procede (non descriptif) de retardement du sida chez des sujets contamines par le vih par administration de composes d'azaspirane substitue
WO1995003042A1 (fr) * 1993-07-23 1995-02-02 Smithkline Beecham Corporation Procede d'inhibition de la replication des virus de l'immunodeficience humaine a l'aide d'azaspirannes substitues
WO1995003046A1 (fr) * 1993-07-23 1995-02-02 Smithkline Beecham Corporation Procede d'inhibition de la production de vih
WO1995003049A1 (fr) * 1993-07-23 1995-02-02 Smithkline Beecham Corporation Procedes de traitement du vih au moyen d'azaspiranes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014462A1 (fr) * 1991-02-19 1992-09-03 Smithkline Beecham Corporation Inhibiteurs de cytokines
WO1993014760A2 (fr) * 1992-01-28 1993-08-05 Smithkline Beecham Corporation Procedes
WO1993015735A1 (fr) * 1992-01-28 1993-08-19 Smithkline Beecham Corporation Procede (non descriptif) de retardement du sida chez des sujets contamines par le vih par administration de composes d'azaspirane substitue
WO1995003042A1 (fr) * 1993-07-23 1995-02-02 Smithkline Beecham Corporation Procede d'inhibition de la replication des virus de l'immunodeficience humaine a l'aide d'azaspirannes substitues
WO1995003046A1 (fr) * 1993-07-23 1995-02-02 Smithkline Beecham Corporation Procede d'inhibition de la production de vih
WO1995003049A1 (fr) * 1993-07-23 1995-02-02 Smithkline Beecham Corporation Procedes de traitement du vih au moyen d'azaspiranes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BADGER A M ET AL: "ANTIARTHRITIC AND SUPPRESSOR CELL INDUCING ACTIVITY OF AZASPIRANES:STRUCTURE-FUNCTION RELATIONSHIPS OF A NOVEL CLASS OF IMMUNOMODULATORY AGENTS" JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, no. 11, November 1990, pages 2963-2970, XP000605424 *
P.S. SARIN ET AL.: "INHIBITION OF HTLV-III REPLICATION IN CELL CULTURES" NATO ASI SER., SER. A, vol. 120, 1986, pages 329-342, XP002069579 *
S. GOODMAN: "THERAPEUTIC EFFECTS OF ORGANIC GERMANIUM" MEDICAL HYPOTHESES, vol. 26, 1988, pages 207-215, XP002069578 *
See also references of WO9503041A1 *

Also Published As

Publication number Publication date
ZA945416B (en) 1995-05-10
NZ269990A (en) 1999-07-29
WO1995003041A1 (fr) 1995-02-02
AU7370894A (en) 1995-02-20
GB9315306D0 (en) 1993-09-08
CA2167841A1 (fr) 1995-02-02
EP0713391A4 (fr) 1998-09-09
CN1130870A (zh) 1996-09-11

Similar Documents

Publication Publication Date Title
DK164441B (da) Anvendelse af et piperidinderivat til fremstilling af et farmaceutisk praeparat til behandling af smertetilstande
UA81003C2 (en) Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450
EP0713391A1 (fr) Procede d'inhibition de la production de virus de l'immunodeficience chez l'homme au moyen d'azaspiranes substitues
EP0711160A1 (fr) Procede d'inhibition de la replication des virus de l'immunodeficience humaine a l'aide d'azaspirannes substitues
US5482959A (en) Method for delaying aids in an HIV infected individual by administration of substituted azaspirane compounds
WO1995003049A1 (fr) Procedes de traitement du vih au moyen d'azaspiranes
AU3595193A (en) A method for delaying HIV induced AIDS by administration of substituted azasperane compounds
AU710542B2 (en) Use of substituted azaspirane in the treatment of asthma
AU684384B2 (en) Method of treating opportunistic infections with azaspiranes
US5786376A (en) Methods of treating opportunistic infections with azaspiranes
WO2020237096A1 (fr) Combinaison pour baisser le phosphate sérique chez un patient
JPH09500647A (ja) 置換アザスピランによるヒト免疫不全ウイルス産生の阻害法
EP0996445A1 (fr) Traitement et prevention de maladies cardiaques au moyen d'inhibiteurs specifiques du recaptage de la serotonine (ssri)
MXPA98009596A (en) Use of azaspiran substituted in the treatment of a
WO1995003048A1 (fr) Azaspiranes anti-hiv
WO1995003046A1 (fr) Procede d'inhibition de la production de vih
WO1995003047A1 (fr) Traitements s'exercant contre le virus de l'immunodeficience chez l'homme
JPS6231682B2 (fr)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 960201

RAX Requested extension states of the european patent have changed

Free format text: SI PAYMENT 960201

A4 Supplementary search report drawn up and despatched

Effective date: 19980722

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990203

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1012278

Country of ref document: HK